Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Gilead beats Street

GILD reported 3Q07 non-GAAP diluted EPS of $0.45, beating the Street's $0.39 estimate by $0.06 and up 32%

Read the full 186 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE